NASDAQ:NLSP NLS Pharmaceutics (NLSP) Stock Price, News & Analysis $3.98 -0.17 (-4.10%) (As of 10:27 AM ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends About NLS Pharmaceutics Stock (NASDAQ:NLSP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get NLS Pharmaceutics alerts:Sign Up Key Stats Today's Range$3.87▼$4.0350-Day Range$0.12▼$5.3452-Week Range$3.51▼$29.08Volume4,254 shsAverage Volume152,713 shsMarket Capitalization$15.18 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewNLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.Read More… The only pattern to trade during election season. (Ad)Over the last 5 years Roger Scott has done some pretty incredible things… He’s found hundreds of winning opportunities… He’s created some incredible strategies… And he’s even designed some amazing tools… But there is one thing he’s always kept close to the chest… And in this case, it’s been a very particular stock market pattern…. A pattern he calls the World's Most Predictable Pattern…Follow this link here and enter your email address to sign up… NLS Pharmaceutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks14th Percentile Overall ScoreNLSP MarketRank™: NLS Pharmaceutics scored higher than 14% of companies evaluated by MarketBeat, and ranked 912th out of 967 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for NLS Pharmaceutics. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioNLS Pharmaceutics has a P/B Ratio of 0.37. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.88% of the float of NLS Pharmaceutics has been sold short.Short Interest Ratio / Days to CoverNLS Pharmaceutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NLS Pharmaceutics has recently increased by 29.18%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNLS Pharmaceutics does not currently pay a dividend.Dividend GrowthNLS Pharmaceutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.88% of the float of NLS Pharmaceutics has been sold short.Short Interest Ratio / Days to CoverNLS Pharmaceutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NLS Pharmaceutics has recently increased by 29.18%, indicating that investor sentiment is decreasing significantly. News and Social Media2.4 / 5News Sentiment0.29 News SentimentNLS Pharmaceutics has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for NLS Pharmaceutics this week, compared to 0 articles on an average week.Search Interest2 people have searched for NLSP on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, NLS Pharmaceutics insiders have not sold or bought any company stock.Percentage Held by Insiders16.40% of the stock of NLS Pharmaceutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about NLS Pharmaceutics' insider trading history. Receive NLSP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NLS Pharmaceutics and its competitors with MarketBeat's FREE daily newsletter. Email Address NLSP Stock News HeadlinesNLS Pharmaceutics Announces Strategic Capital RestructuringNovember 7 at 1:09 AM | markets.businessinsider.comNLS Pharmaceutics and Kadimastem Announce Strategic MergerNovember 6 at 10:05 AM | markets.businessinsider.com625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.November 8, 2024 | Crypto Swap Profits (Ad)NLS Pharmaceutics (NASDAQ:NLSP) Stock, Short Interest ReportNovember 4, 2024 | benzinga.comNLS Pharmaceutics, Kadimastem enter definitive merger agreementNovember 4, 2024 | markets.businessinsider.comNLS Pharmaceutics Merges with Kadimastem for Strategic GrowthNovember 4, 2024 | markets.businessinsider.comWhat's Going On With NLS Pharmaceutics Shares Monday?November 4, 2024 | msn.comNLS Pharmaceutics stock jumps 50% on merger agreement with cell therapy firm KadimastemNovember 4, 2024 | msn.comSee More Headlines NLSP Stock Analysis - Frequently Asked Questions How have NLSP shares performed this year? NLS Pharmaceutics' stock was trading at $0.5899 at the start of the year. Since then, NLSP shares have increased by 603.5% and is now trading at $4.15. View the best growth stocks for 2024 here. When did NLS Pharmaceutics IPO? NLS Pharmaceutics (NLSP) raised $20 million in an initial public offering on Friday, January 29th 2021. The company issued 3,600,000 shares at $5.00-$6.00 per share. Maxim Group LLC acted as the underwriter for the IPO and Brookline Capital (A division of Arcadia Securities) was co-manager. How do I buy shares of NLS Pharmaceutics? Shares of NLSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of NLS Pharmaceutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that NLS Pharmaceutics investors own include Intel (INTC), Meta Platforms (META), Immunic (IMUX), Seres Therapeutics (MCRB), NVIDIA (NVDA), Palantir Technologies (PLTR) and Tesla (TSLA). Company Calendar Today11/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NLSP CUSIPN/A CIK1783036 Webwww.nlspharma.com Phone41-44-512-2150Fax41-41-618-8009Employees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.15 Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$11.14 per share Price / Book0.37Miscellaneous Outstanding Shares3,815,000Free Float3,189,000Market Cap$15.83 million OptionableNot Optionable Beta-0.51 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report This page (NASDAQ:NLSP) was last updated on 11/8/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredWhat Trump’s victory means for GOLDGold may have suffered a pullback after news of Trump's 2024 election win spread... But don't be mistaken: ...Stansberry Research | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredTrump’s Victory Just Kicked the Door Open to a…This story is about a division that has been splitting America apart at the seams for the past three and a hal...Banyan Hill Publishing | SponsoredUrgent: This election is riggedI’d like to share with you my #1 high-conviction stock to buy before Inauguration Day… and details on the asse...Porter & Company | SponsoredJD Vance Exposes Wall Street’s Secret Plot Against TrumpTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purpose...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NLS Pharmaceutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NLS Pharmaceutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.